BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 34998477)

  • 1. Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study.
    Tarca AL; Taran A; Romero R; Jung E; Paredes C; Bhatti G; Ghita C; Chaiworapongsa T; Than NG; Hsu CD
    Am J Obstet Gynecol; 2022 Jan; 226(1):126.e1-126.e22. PubMed ID: 34998477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population.
    Chaemsaithong P; Pooh RK; Zheng M; Ma R; Chaiyasit N; Tokunaka M; Shaw SW; Seshadri S; Choolani M; Wataganara T; Yeo GSH; Wright A; Leung WC; Sekizawa A; Hu Y; Naruse K; Saito S; Sahota D; Leung TY; Poon LC
    Am J Obstet Gynecol; 2019 Dec; 221(6):650.e1-650.e16. PubMed ID: 31589866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal vascular indices at 36 weeks' gestation in the prediction of preeclampsia.
    Mansukhani T; Wright A; Arechvo A; Lamanna B; Menezes M; Nicolaides KH; Charakida M
    Am J Obstet Gynecol; 2024 Apr; 230(4):448.e1-448.e15. PubMed ID: 37778678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis.
    Chaemsaithong P; Gil MM; Chaiyasit N; Cuenca-Gomez D; Plasencia W; Rolle V; Poon LC
    Am J Obstet Gynecol; 2023 Sep; 229(3):222-247. PubMed ID: 36990308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).
    Chaiworapongsa T; Romero R; Erez O; Tarca AL; Conde-Agudelo A; Chaemsaithong P; Kim CJ; Kim YM; Kim JS; Yoon BH; Hassan SS; Yeo L; Korzeniewski SJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):682.e1-682.e13. PubMed ID: 29037482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
    Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
    Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
    Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial.
    Benkő Z; Wright A; Rehal A; Cimpoca B; Syngelaki A; Delgado JL; Tsokaki T; De Alvarado M; Vojtassakova D; Malligiannis Ntalianis K; Chaveeva P; Del Campo A; De Ganzo T; Resta C; Atanasova V; Accurti V; Villalain C; Aguilera J; Dojcinovska D; O'Gorman N; Plasencia W; Zingler E; Dutemeyer V; Alvar B; Casanova MC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Feb; 57(2):257-265. PubMed ID: 33142361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of imminent preeclampsia at 35-37 weeks gestation.
    Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume.
    Sonek J; Krantz D; Carmichael J; Downing C; Jessup K; Haidar Z; Ho S; Hallahan T; Kliman HJ; McKenna D
    Am J Obstet Gynecol; 2018 Jan; 218(1):126.e1-126.e13. PubMed ID: 29097177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.
    Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS
    Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preterm preeclampsia screening using biomarkers: combining phenotypic classifiers into robust prediction models.
    Thomas G; Syngelaki A; Hamed K; Perez-Montaño A; Panigassi A; Tuytten R; Nicolaides KH
    Am J Obstet Gynecol MFM; 2023 Oct; 5(10):101110. PubMed ID: 37752025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
    O'Gorman N; Wright D; Syngelaki A; Akolekar R; Wright A; Poon LC; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jan; 214(1):103.e1-103.e12. PubMed ID: 26297382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ophthalmic artery Doppler in the prediction of preeclampsia.
    Nicolaides KH; Sarno M; Wright A
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1098-S1101. PubMed ID: 34292158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
    Tan MY; Syngelaki A; Poon LC; Rolnik DL; O'Gorman N; Delgado JL; Akolekar R; Konstantinidou L; Tsavdaridou M; Galeva S; Ajdacka U; Molina FS; Persico N; Jani JC; Plasencia W; Greco E; Papaioannou G; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Aug; 52(2):186-195. PubMed ID: 29896812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.